Joshua D. Lee, MD, MSc
NYU Langone Health - Professor, Department of Population Health, Division of General Medicine and Clinical Innovation
Email: Joshua.Lee@nyulangone.org
Education
MD, University of Tennessee College of MedicineMSc, Weill Cornell Graduate School of Medical Sciences
AB, Art and Archeology, Princeton University
Research Interests
Addiction pharmacotherapies, Primary care, Criminal justice BIO
Joshua D. Lee is a Professor of Population Health and Medicine/General Internal Medicine and Clinical Innovation at NYU Langone Health. He is a clinician researcher focused on addiction pharmacotherapies, and is Director of the NYU ABAM Fellowship in Addiction Medicine. His research models the use of addiction pharmacotherapies in primary care and criminal justice populations. He has conducted multiple NIH and other clinical trials examining the use of extended-release naltrexone and buprenorphine opioid treatments in outpatient criminal justice involved-adults, in soon-to-be released jail inmates, and in community detox settings. Research on extended-release naltrexone for alcohol treatment has focused on primary care medical management. Dr. Lee graduated Princeton University (AB), the University of Tennessee School of Medicine (MD), and Weill Cornell Graduate School of Medical Sciences (MSc). He completed a residency and chief residency in Primary Care Internal Medicine at NYU/Bellevue Hospital Center and is certified in Addiction Medicine. He is currently an attending physician at Bellevue Hospital and in the New York City jails. Projects
Principal Investigator, Impact of Jail-Based Methadone on Overdose, Recidivism, HIV and Health Outcomes, and Costs in New York City, 2011-2017. Active
Principal Investigator, Long-Acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-Involved Adults. Active
Principal Investigator, Extended-Release Naltrexone Opioid Treatment at Jail-to-Community Re-Entry. Completed
Principal Investigator, Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care. Completed
Publications
Recent
Christine PJ, Lodi S, Hsu HE, Bovell-Ammon B, Yan S, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz J, Walley AY, Larochelle MR (2024).
Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder
Addiction [Epub 2024 Mar 22]. doi: 10.1111/add.16473.
Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder
Addiction [Epub 2024 Mar 22]. doi: 10.1111/add.16473.
Lim S, Cherian T, Katyal M, Goldfeld KS, McDonald R, Wiewel E, Khan M, Krawczyk N, Braunstein S, Murphy SM, Jalali A, Jeng PJ, Rosner Z, MacDonald R, Lee JD (2024).
Jail-based medication for opioid use disorder and patterns of reincarceration and acute care use after release: A sequence analysis
Journal of Substance Use and Addiction Treatment, 158, 209254. doi: 10.1016/j.josat.2023.209254. PMCID: PMC10947890.
Jail-based medication for opioid use disorder and patterns of reincarceration and acute care use after release: A sequence analysis
Journal of Substance Use and Addiction Treatment, 158, 209254. doi: 10.1016/j.josat.2023.209254. PMCID: PMC10947890.
Shulman M, Choo TH, Scodes J, Pavlicova M, Novo P, Campbell ANC, Greiner M, Lee JD, Rotrosen J, Nunes EV (2023).
Secondary analysis of agreement between negative timeline follow back report and negative urine toxicology in a large trial of individuals with opioid use disorder
Journal of Addiction Medicine, 17 (5), 618-620. doi: 10.1097/ADM.0000000000001173. PMCID: PMC10593984.
Secondary analysis of agreement between negative timeline follow back report and negative urine toxicology in a large trial of individuals with opioid use disorder
Journal of Addiction Medicine, 17 (5), 618-620. doi: 10.1097/ADM.0000000000001173. PMCID: PMC10593984.
Tofighi B, Badiei B, Badolato R, Lewis CF, Nunes E, Thomas A, Lee JD (2023).
Integrating text messaging in a low threshold telebuprenorphine program for New York City residents with opioid use disorder during COVID-19: A pilot randomized controlled trial
Journal of Addiction Medicine, 17 (5), e281-e286. doi: 10.1097/ADM.0000000000001161. PMCID: PMC10544683.
Integrating text messaging in a low threshold telebuprenorphine program for New York City residents with opioid use disorder during COVID-19: A pilot randomized controlled trial
Journal of Addiction Medicine, 17 (5), e281-e286. doi: 10.1097/ADM.0000000000001161. PMCID: PMC10544683.
Tofighi B, Marini C, Lee JD, Garland EL (2023).
Patient perceptions of integrating meditation-based interventions in office-based opioid treatment with buprenorphine: A mixed-methods survey
Journal of Addiction Medicine, 17 (5), 517-520. doi: 10.1097/ADM.0000000000001160. PMCID: PMC10533745.
Patient perceptions of integrating meditation-based interventions in office-based opioid treatment with buprenorphine: A mixed-methods survey
Journal of Addiction Medicine, 17 (5), 517-520. doi: 10.1097/ADM.0000000000001160. PMCID: PMC10533745.
Notable
Extended-release naltrexone to prevent opioid relapse in criminal justice offenders
New England Journal of Medicine, 374 (13), 1232-1242. doi: 10.1056/NEJMoa1505409. PMCID: PMC5454800.
Lee JD, McDonald R, Grossman E, McNeely J, Laska E, Rotrosen J, Gourevitch MN (2015).
Opioid treatment at release from jail using extended-release naltrexone: A pilot proof-of-concept randomized effectiveness trial
Addiction, 110 (6), 1008-1014. doi: 10.1111/add.12894.
Lee JD, Grossman E, Truncali A, Rotrosen J, Rosenblum A, Magura S, Gourevitch M (2012).
Buprenorphine-naloxone maintenance following release from jail
Substance Abuse, 33 (1), 40-47. doi: 10.1080/08897077.2011.620475. PMCID: PMC3310898.
Dr. Lee's MyBibliography Profile
Selected Press